top of page
Search
  • Writer's pictureSarah-Jane Butler

Shortage in ADHD medication is reported from September 2023

GPs have been advised not to start new patients on several drugs for treating attention deficit/hyperactivity disorder that are in short supply in the UK, said the Department of Health and Social Care, because of a combination of manufacturing problems and increasing global demand. www.bmj.com

Shortages reported in the following:

Methylphenidate:

• Equasym XL® 10, 20 and 30 mg capsules

• Xaggitin XL® 18 and 36 mg prolonged-release tablets

• Concerta XL® 54 mg prolonged-release tablets

• Xenidate XL® 27 mg prolonged-release tablets

Lisdexamfetamine:

• Elvanse® 20, 30, 40, 50, 60 and 70 mg capsules

• Elvanse® Adult 30, 50, and 70 mg capsules

Guanfacine:

• Intuniv® 1, 2, 3 and 4 mg prolonged-release tablets

If your medication is currently affected by the shortage and you require a prescription, you have the following options:

1. Get the prescriptions sent directly to your home or pick it up in our clinic and contact local pharmacies. Some pharmacies might have stock left or restock small amounts.

2. Book a medication review to get changed to a different medication for the time of the shortage.

3. Wait until your medication is back in stock.

Credit www.adhddirect.co.uk

6 views0 comments

Recent Posts

See All

NHS establish ADHD taskforce

NHS England is establishing a taskforce to look at attention deficit hyperactivity disorder (ADHD) service provision and its impact on patient experience. We know that ADHD can have a lifetime impact,

From CEO of ADHD UK

“ADHD is only diagnosed when it is having a debilitating impact on your life. The over 2 million people who have ADHD and no diagnose are defacto struggling. A diagnosis, and the understanding and sup

Comments


bottom of page